All Reports Events Blogs Videos
Showing 12 results
  • PEAK Matrix®
    Sep. 30, 2026

    Pharmaceutical enterprises are under growing pressure to improve R&D productivity as development costs rise, scientific and therapeutic complexity increases, and timelines remain long. At the same time, advances in AI, generative AI, agentic AI, scientific computing,…
  • PEAK Matrix®
    Sep. 29, 2026

    Life sciences companies are operating in an increasingly complex regulatory environment shaped by evolving health authority requirements, regional differences, growing submission volumes, and pressure to accelerate approvals. Limited specialist talent, fragmented operating models, and inconsistent regulatory…
  • Viewpoint
    June 29, 2026

    The post-approval phase represents one of the most complex and strategically critical stages in the life sciences product life cycle, requiring enterprises to ensure continuous safety monitoring, regulatory compliance, and real-world performance optimization. With increasing diverse…
  • Thematic Report
    May 04, 2026

    The global Clinical Research Organization (CRO) market is undergoing a transformation, shaped by rising clinical trial complexity, increasing regulatory requirements, and growing demand for faster, more efficient drug development. CROs continue to play a pivotal role…
  • Viewpoint
    April 28, 2026

    The global safety database market is at an inflection point, driven by increasing complexities in Pharmacovigilance (PV) operations, growing regulatory expectations, and rapid expansion of data sources such as real-world evidence, digital health tools, and patient-generated…
  • State of the Market
    Oct. 01, 2025

    The surge in case volumes, more stringent regulatory demands, and therapeutic areas’ rising complexities are significantly transforming pharmacovigilance (PV). As the industry adapts to more tailored reporting requirements and longer patient monitoring periods, enterprises are under…
  • Provider Compendium
    Sep. 30, 2025

    In recent years, life sciences enterprises have reoriented their R&D investments, prioritizing pipeline efficiency and a strategic focus on large and novel molecules. This shift has intensified efforts around cost containment and created a stronger need…
  • PEAK Matrix®
    July 16, 2025

    In recent years, life sciences enterprises have reprioritized and overhauled their R&D investments. They now focus on streamlining their pipelines and shifting toward new and large molecules. This transformation has compelled aggressive cost containment initiatives, prompting…
  • Discovery
    March 04, 2025

    Discoveries focus on specific science and technology innovations that address today’s critical business issues and challenges. These brief yet detailed profiles highlight innovations across the world's leading companies, start-ups, universities, institutes, and the entire R&D ecosystem…
  • Discovery
    Jan. 31, 2025

    Discoveries focus on specific science and technology innovations that address today’s critical business issues and challenges. These brief yet detailed profiles highlight innovations across the world's leading companies, start-ups, universities, institutes, and the entire R&D ecosystem…